Editorial and Publishing Staff

Article

John C. Hayes Editorial DirectorShalmali Pal News EditorAnne Landry, Ronald Piana Feature EditorsTerri Gelfand Managing EditorLisa Katz Creative DirectorNancy Bitteker Group Creative DirectorCarolyn Harrington Art DirectorBarbara Boughton, Catherine Donnelly, Jordana Bieze Foster, Caroline Helwick, Susan London, June Skinner, Kathlyn Stone, Steven Wagner Contributing WritersAndrew Barkus Group Production ManagerAmy Birnbach Associate PublisherChrissy Sheehan Advertising CoordinatorCara H. Glynn Senior Editorial DirectorKathy Mischak Group PublisherBeth Scholz Senior Vice President, Oncology and RadiologyBeatrix Eriksen Vice President, Research Marketing, and CirculationAmy Erdman Director of ResearchColleen Tricarico Circulation Manager

John C. Hayes
Editorial Director
Shalmali Pal
News Editor
Anne Landry, Ronald Piana
Feature Editors
Terri Gelfand
Managing Editor
Lisa Katz
Creative Director
Nancy Bitteker
Group Creative Director
Carolyn Harrington
Art Director
Barbara Boughton, Catherine Donnelly, Jordana Bieze Foster, Caroline Helwick, Susan London, June Skinner, Kathlyn Stone, Steven Wagner
Contributing Writers
Andrew Barkus
Group Production Manager
Amy Birnbach
Associate Publisher
Chrissy Sheehan
Advertising Coordinator
Cara H. Glynn
Senior Editorial Director
Kathy Mischak
Group Publisher
Beth Scholz
Senior Vice President, Oncology and Radiology
Beatrix Eriksen
Vice President, Research Marketing, and Circulation
Amy Erdman
Director of Research
Colleen Tricarico
Circulation Manager

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
2 experts are featured in this series.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
Related Content
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

Atilla Soran, MD, MPH;Kazim Senol;Schlomo Schneebaum;Shigeru Imoto;Carole Mathelin;Alexander Mundinger;Meltem Selam;Vahit Ozmen
April 21st 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

Tim Cortese
April 21st 2025
Article

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Roman Fabbricatore
April 21st 2025
Article

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

3 Things You Should Know About Unresectable NSCLC

3 Things You Should Know About Unresectable NSCLC

ONCOLOGY Staff
April 21st 2025
Article

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.